ions.bio

Executive Summary

ions.bio is a Munich-based biomarker discovery company that offers an end-to-end, AI-driven platform for converting biosamples into actionable multi-omics datasets. Founded in 2020, the company integrates biomarker study design, clinical sample collection, lab processing, and proprietary bioinformatics/ML analysis to identify novel biomarkers. Its all-in-one approach aims to accelerate drug development and precision medicine by providing clients with high-quality, integrated biomarker data without the need to coordinate multiple vendors. The biomarker market is growing rapidly, driven by the push for personalized therapies and companion diagnostics, and ions.bio is well-positioned to capture value with its comprehensive service model.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q3 2026Major Pharma Partnership (e.g., for oncology biomarker study)60% success
• Q3 2026Launch of Proprietary AI Platform for Real-Time Biomarker Analytics50% success